Education
About Us
Working with TipRanks
Follow Us
Fortress Biotech (FBIO)
NASDAQ:FBIO
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.75Last Year’s EPS
-1.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -2.56%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant achievements like the successful launch of Emrosi, strong cash position, and positive clinical data publications. However, these were offset by challenges such as decreased net product revenue, increased net loss, and initial payer coverage hurdles for Emrosi.Company Guidance
During the Journey Medical's 2024 Financial Results and Corporate Update Conference Call, the management highlighted several key metrics and developments. The company reported an annual revenue of $56 million, with the fourth quarter marking the sixth consecutive quarter of positive non-GAAP adjusted EBITDA. Journey Medical successfully launched Emrosi, an oral treatment for Rosacea, after receiving first cycle FDA approval in November 2024. They also completed $22 million in FDA filing fees and milestone payments to Dr. Reddy Labs. As of December 31, 2024, the company maintained a strong balance sheet with $20.3 million in cash. Despite a net loss of $14.7 million, or $0.72 per share, Journey Medical achieved a positive non-GAAP adjusted EBITDA of $800,000, or $0.04 per share basic. The company anticipates significant growth opportunities with Emrosi entering a $1 billion treatment category, aiming for peak annual sales of $200 million in the U.S. and $100 million internationally.Successful Launch of Emrosi
Journey Medical launched Emrosi, an oral treatment for Rosacea, after receiving FDA approval in November 2024. The product is expected to be transformational, entering a $1 billion treatment category.
Revenue Achievements
Annual revenue for 2024 was reported at $56 million, with the company achieving positive non-GAAP adjusted EBITDA for the sixth consecutive quarter.
Regulatory Milestones Completed
Journey Medical completed all financial obligations related to Emrosi's regulatory fees and development milestones in the U.S., clearing the way for its commercial debut.
Strong Cash Position
Despite significant payments, Journey Medical maintained a strong balance sheet with $20.3 million in cash as of December 31, 2024.
Significant Interest at AAD Conference
The company reported high interest and engagement at the 2025 AAD Conference, supporting a strong launch for Emrosi.
Positive Peer-Reviewed Publications
Phase 3 results of Emrosi were published in JAMA Dermatology, highlighting its clinical superiority and favorable safety profile.
---
FBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $1.56 | $1.54 | -1.28% |
| Nov 14, 2024 | $1.57 | $1.43 | -8.92% |
| Aug 13, 2024 | $1.83 | $1.81 | -1.09% |
| May 08, 2024 | $1.78 | $1.75 | -1.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fortress Biotech (FBIO) report earnings?
Fortress Biotech (FBIO) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Fortress Biotech (FBIO) earnings time?
Fortress Biotech (FBIO) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FBIO EPS forecast?
FBIO EPS forecast for the fiscal quarter 2025 (Q1) is -0.75.
---